This study looked at the benefit of oral CFA on knee
range of motion and function in patients with OA.
Dietary fatty acid composition is important for the
prevention of chronic disease. Recent studies have suggested
that myriostoleic acid (one of the CFA in Celadrin)
may act by inhibition of 5-lipoxygenase, a potent mediator
in the inflammatory process
METHODS AND MATERIALS
64 patients with chronic knee OA were evaluated at baseline
and at 30 and 68 days after consuming either placebo
(vegetable oil; n=31) or CFA capsules (Celadrin; n=33).
Subjects and investigators were blinded to the treatment
assignment. Amber coloured soft gel capsules identical
in shape and size were used to blind study participants.
Participants were asked to consume 6 capsules per day
with makeup days allowed for missed dosages. Patients
were asked to consume 3 capsules in the morning and
3 in the evening.
Clinical evaluation at 30 and 68 days included physician
assessment for pain, stiffness and discomfort, knee
range of motion with goniometry, and the Lequesne Algofunctional
RESULTS AND CONCLUSIONS
After 68 days, patients treated with CFA exhibited significant
increase in knee flexion compared to patients given
the placebo. Neither group reported improvement in knee
extension. In the CFA group 58% of patients experienced
a reduction in pain compared to 32% of patients given
placebo. Neither group exhibited changes in morning
stiffness. Patient responses to the LAI indicated a
significant shift towards functional improvement for
the CFA group in all four response categories after
68 days. This was not observed in the placebo group.
Therefore, compared to the placebo group, CFA provides
an improvement in knee range of motion and overall function
in patients with OA of the knee. CFA may be an alternative
to the use of nonsteroidal anti-inflammatory drugs for
the treatment of OA.